The U.S. P2Y12 inhibitors market comprises drugs that block the P2Y12 receptor and inhibit platelet aggregation. These drugs are widely used to prevent blood clots in cardiovascular disorders like myocardial infarction and stroke. P2Y12 inhibitors help reduce the risk of recurrent cardiovascular events by decreasing platelet reactivity. Clopidogrel, ticagrelor, prasugrel, and cangrelor are some commonly used P2Y12 inhibitors. Growing prevalence of cardiovascular diseases, rising geriatric population susceptible to heart ailments, and increasing uptake of antiplatelet drugs for secondary stroke prevention are fueling the demand for P2Y12 inhibitors in the country.

The U.S. P2Y12 Inhibitors Market is estimated to be valued at US$ 267.73 Mn in 2024 and is expected to exhibit a CAGR of 6.5% over the forecast period 2024 To 2031.

Key Takeaways

Key players operating in the U.S. P2Y12 inhibitors market are Abcam plc, Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., BD Biosciences, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., BioLegend, Inc., Merck KGaA, Novus Biologicals, LLC, R&D Systems, Inc. (a Bio-Techne brand), Santa Cruz Biotechnology, Inc., Beckman Coulter, Inc., Miltenyi Biotec GmbH, GeneTex, Inc., MBL International Corporation. The key players are increasingly investing in R&D activities to develop advanced drugs with enhanced efficacy and fewer side effects.

The U.S P2Y12 Inhibitors Market Demand provides lucrative opportunities for players to launch new drugs with better safety profiles and expanded indications. Further, rising healthcare awareness and spending on cardiovascular diseases will drive the demand for advanced antiplatelet therapies in the country.

The increasing cases of cardiovascular disorders worldwide have compelled major market players to focus on expanding their global footprint. Developed regions like North America and Europe currently dominate the global P2Y12 inhibitors market. However, emerging markets like Asia Pacific and Latin America are expected to offer high revenue potential over the coming years.

Get More Insights On, U.S. P2Y12 Inhibitors Market